Queen's University Belfast and Santen to Present Opening Keynote this November

WESTMINSTER, U.K. - Sept. 6, 2018 - PRLog -- Hear from Queen's University Belfast and Santen as they present the opening addresses this November.

Day 1 – Opening Keynote Address: New Strategies for Treating Retinal Vascular Diseases

Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the clinical management of these diseases has been fast-paced, with new treatments becoming available as well as license extensions of existing treatments.*

Discover advancements in the treatment of ocular diseases as Professor Alan Stitt, Dean of Innovation and Impact, Queen's University Belfast presents an overview of pathogenesis of ischaemic retinopathies, a disease that affects the immature retinal vascular system, as well as the cellular and molecular mechanisms of the disease. Check out the full presentation details online, as Professor Stitt looks ahead to new treatment pathways and improved use of preclinical evidence in the clinical setting to aid translation.

Day 2 – Opening Keynote Address: Glaucoma / retinoprotection treatments

Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in glaucoma remains incompletely understood and a broad range of possible mechanisms have been implicated.*

Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen, USA will present the latest developments in the treatment of glaucoma, which will explore the novel and recently approved drugs in view, new devices to lower and control IOP and a case for pathways to retinoprotection.

Here's a few of our last year's attendees:

Aerie Pharmaceuticals | Alimera Sciences | Altacor, Ltd | Annexin Pharmaceuticals AB | APTAR PHARMA | Bayer (Schweiz) AG | Biozep AS | Boehringer Ingelheim Pharma GmbH & Co. KG | Elasmogen Ltd | Experimentica Ltd | Fresenius-Kabi | Leica Microsystems UK Ltd | MHRA | Midland Eye | Nanoptima Ltd | NEMERA | nicox | NightstarX | Novaliq GmbH | Optos | Ora Inc | Oxford BioMedica | Partner Grup Pazarlama Iletisimi ve Tur Tic Ltd Sti | Pharmaleads | PharmaMedic Consultancy Ltd | Roche | Roche Diagnostics Ltd | Roche Products Ltd | Santen Incorporated | Shire | Similasan + more!

Download the full 2017 attendee list in the download centre: www.ophthalmicdrugs.com/prl

For those looking to attend, there is currently a £200 early-bird saving, ending September 28th.

SMi Presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/prl

Sponsors: Experimentica | Nemera

Sources: https://bit.ly/2BVa7lS | https://go.nature.com/2PEYouy

Follow 'SMi Pharma' on LinkedIn for latest pharmaceutical industry updates.

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk